Charles Dumontet

30.2k total citations · 6 hit papers
377 papers, 20.7k citations indexed

About

Charles Dumontet is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Charles Dumontet has authored 377 papers receiving a total of 20.7k indexed citations (citations by other indexed papers that have themselves been cited), including 169 papers in Molecular Biology, 156 papers in Oncology and 66 papers in Hematology. Recurrent topics in Charles Dumontet's work include Chronic Lymphocytic Leukemia Research (48 papers), Lymphoma Diagnosis and Treatment (45 papers) and Cancer Treatment and Pharmacology (38 papers). Charles Dumontet is often cited by papers focused on Chronic Lymphocytic Leukemia Research (48 papers), Lymphoma Diagnosis and Treatment (45 papers) and Cancer Treatment and Pharmacology (38 papers). Charles Dumontet collaborates with scholars based in France, United States and Canada. Charles Dumontet's co-authors include Mary Ann Jordan, Alain Beck, Lars Petter Jordheim, Carlos M. Galmarini, Nathalie Corvaı̈a, Liliane Goetsch, John R. Mackey, P. Sève, Branimir I. Šikić and Gilles Salles and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Blood.

In The Last Decade

Charles Dumontet

370 papers receiving 20.2k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Strategies and challenges for the next generation of antibody–drug conjugates

2017 1.6k citations Charles Dumontet et al. profile →
Microtubule-binding agents: a dynamic field of cancer therapeutics

2010 1.4k citations Charles Dumontet et al. profile →
Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases

2013 926 citations Lars Petter Jordheim, Charles Dumontet et al. profile →
Antibody–drug conjugates come of age in oncology

2023 460 citations Charles Dumontet et al. profile →
Antibody–Drug Conjugates: The Last Decade

2020 268 citations Charles Dumontet et al. profile →
Payload diversification: a key step in the development of antibody–drug conjugates

2023 138 citations Warren Viricel, Charles Dumontet et al. profile →

Peers

Charles Dumontet

ONCOL

PFM

HEMAT

Edward A. Sausville United States

James A. McCubrey United States

Patricia LoRusso United States

Steven Grant United States

Herbert M. Pinedo Netherlands

Éric Raymond France

Godefridus J. Peters Netherlands

Neal Rosen United States

Takashi Tsuruo Japan

Joseph R. Bertino United States

Edward A. Sausville United States

Charles Dumontet

19.3k ×2.1

11.7k ×1.4

ONCOL

2.5k ×0.8

PFM

2.7k ×1.2

2.1k ×1.0

HEMAT

Citations per year, relative to Charles Dumontet Charles Dumontet (= 1×) peers Edward A. Sausville

Countries citing papers authored by Charles Dumontet

Since Specialization

Citations

This map shows the geographic impact of Charles Dumontet's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charles Dumontet with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charles Dumontet more than expected).

Fields of papers citing papers by Charles Dumontet

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Charles Dumontet. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charles Dumontet. The network helps show where Charles Dumontet may publish in the future.

Co-authorship network of co-authors of Charles Dumontet

This figure shows the co-authorship network connecting the top 25 collaborators of Charles Dumontet. A scholar is included among the top collaborators of Charles Dumontet based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Charles Dumontet. Charles Dumontet is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cros‐Perrial, Emeline, et al.. (2025). SLX4 and XPF are involved in cell migration and EMT in a cell-specific manner. Biochemical Pharmacology. 236. 116885–116885.

Xiong, Wei, Ting Wu, Frédérique Ponce, et al.. (2025). Beyond Rodents: Alternative Animal Models in Colorectal Cancer Research. International Journal of Molecular Sciences. 26(22). 10874–10874.

Rébillard, Amélie, Amandine Thomas, Eva‐Laure Matera, et al.. (2024). Combined effects of exercise and immuno-chemotherapy treatments on tumor growth in MC38 colorectal cancer-bearing mice. Frontiers in Immunology. 15. 1368550–1368550. 6 indexed citations

Chettab, Kamel, Chantel Fitzsimmons, А. В. Новиков, et al.. (2023). A systemically administered detoxified TLR4 agonist displays potent antitumor activity and an acceptable tolerance profile in preclinical models. Frontiers in Immunology. 14. 1066402–1066402. 6 indexed citations

Matera, Eva‐Laure, et al.. (2023). Impact of mouse model tumor implantation site on acquired resistance to anti-PD-1 immune checkpoint therapy. Frontiers in Immunology. 13. 1011943–1011943. 6 indexed citations

Robert, Maud, et al.. (2023). Contribution of Mesenchymal Stem Cells from Obese Adipose Tissue to PD-L1 Over-Expression and Breast Cancer Progression through Pathogenic Th17 Cell Activation. Cancers. 15(11). 2963–2963. 3 indexed citations

Wierinckx, Anne, Kamel Chettab, Fabian Birzele, et al.. (2022). In Vivo Syngeneic Tumor Models with Acquired Resistance to Anti–PD-1/PD-L1 Therapies. Cancer Immunology Research. 10(8). 1013–1027. 18 indexed citations

Chettab, Kamel, Marie Potier‐Cartereau, Lars Petter Jordheim, et al.. (2020). Calcium Channel Blockers Impair the Antitumor Activity of Anti-CD20 Monoclonal Antibodies by Blocking EGR-1 Induction. Molecular Cancer Therapeutics. 19(11). 2371–2381. 4 indexed citations

Viricel, Warren, et al.. (2019). Monodisperse polysarcosine-based highly-loaded antibody-drug conjugates. Chemical Science. 10(14). 4048–4053. 68 indexed citations

10.

Dumontet, Charles, et al.. (2018). Real life management of patients hospitalized with multiple myeloma in France. PLoS ONE. 13(5). e0196596–e0196596. 6 indexed citations

11.

Magrangeas, Florence, Rowan Kuiper, Hervé Avet‐Loiseau, et al.. (2016). A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma. Clinical Cancer Research. 22(17). 4350–4355. 30 indexed citations

12.

Cornet, Sébastien, et al.. (2016). Pegfilgrastim Enhances the Antitumor Effect of Therapeutic Monoclonal Antibodies. Molecular Cancer Therapeutics. 15(6). 1238–1247. 11 indexed citations

13.

Viel, Sébastien, Laurie Besson, Emily Charrier, et al.. (2016). Alteration of Natural Killer cell phenotype and function in obese individuals. Clinical Immunology. 177. 12–17. 90 indexed citations

14.

Deckert, Jutta, Marie-Cécile Wetzel, Laura M. Bartle, et al.. (2014). SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies. Clinical Cancer Research. 20(17). 4574–4583. 245 indexed citations

15.

Jordheim, Lars Petter, Eva‐Laure Matera, Anne‐Laure Huber, et al.. (2013). Therapeutic Enhancement of ER Stress by Insulin-Like Growth Factor I Sensitizes Myeloma Cells to Proteasomal Inhibitors. Clinical Cancer Research. 19(13). 3556–3566. 13 indexed citations

16.

Dalle, Stéphane, Lina Reslan, Frank Herting, et al.. (2011). Preclinical Studies on the Mechanism of Action and the Anti-Lymphoma Activity of the Novel Anti-CD20 Antibody GA101. Molecular Cancer Therapeutics. 10(1). 178–185. 97 indexed citations

17.

Hage‐Sleiman, Rouba, et al.. (2011). Silencing of Tubulin Binding Cofactor C Modifies Microtubule Dynamics and Cell Cycle Distribution and Enhances Sensitivity to Gemcitabine in Breast Cancer Cells. Molecular Cancer Therapeutics. 10(2). 303–312. 8 indexed citations

18.

Dumontet, Charles, Maryla Krajewska, Isabelle Treilleux, et al.. (2010). BCIRG 001 Molecular Analysis: Prognostic Factors in Node-Positive Breast Cancer Patients Receiving Adjuvant Chemotherapy. Clinical Cancer Research. 16(15). 3988–3997. 33 indexed citations

19.

Vispé, Stéphane, Laurent Créancier, Jesper Q. Svejstrup, et al.. (2009). Triptolide is an inhibitor of RNA polymerase I and II–dependent transcription leading predominantly to down-regulation of short-lived mRNA. Molecular Cancer Therapeutics. 8(10). 2780–2790. 141 indexed citations

20.

Galmarini, Carlos M., Isabelle Treilleux, Fátima Cardoso, et al.. (2008). Class III β-Tubulin Isotype Predicts Response in Advanced Breast Cancer Patients Randomly Treated Either with Single-Agent Doxorubicin or Docetaxel. Clinical Cancer Research. 14(14). 4511–4516. 55 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact